RICHARDSON, Texas, July 20 /PRNewswire/ -- Zyvex today announced financial results for its fiscal second quarter 2004. The Texas company continues to exceed sales projections with seven consecutive quarters of sales growth. Executives expect Zyvex to realize over $8 million in sales this year, coupled with a sizeable order backlog. Founded in 1997, Zyvex reported its first revenues in 2001, grossing only $150,000. Company revenues grew to $1.2 million in 2002 and $4.5 million in 2003.

"I have been very pleased to watch Zyvex's rapid transformation from a small research center to one of the largest and most promising commercial nanotechnology companies in the world," said Zyvex CFO, Timothy M. Gilmore. "Our continued sales growth demonstrates our leadership in providing real- world, practical nanotechnology solutions."

Gilmore predicts that the company will hit cash-flow break-even in the fourth quarter of 2005, and become bottom-line profitable in 2006.

This followed on the announcements of Zyvex's continued worldwide sales and marketing expansion into China, France, Germany, Italy, Japan, Korea, Malaysia, Singapore, Switzerland, Taiwan, Thailand, the United Kingdom, and Vietnam through alliances with Keithley Instruments, Inc., Caltron, Pte., and LOT-Oriel. Zyvex also has numerous key alliances with industry leaders, including FEI Company, Frost & Sullivan, MIT's Institute for Soldier Nanotechnologies, MANCEF and many others.

Zyvex continues to advance its growth through the introduction of Materials, Tools and Structures for real world nanotechnology applications across major markets serving Health Care, Electronics, Telecommunications, Aerospace, Semiconductor, Energy, and Defense customers.

In April 2004, Zyvex introduced the first two products in its NanoSolve(TM) line of composite additives. The company also announced its Supply Chain Certification Program for carbon nanotube suppliers.

Zyvex also recently announced a breakthrough probing application for integrated circuit (IC) defect analysis. Zyvex enables rapid-response semiconductor device failure analysis at the contact level -- a critical requirement for the highly-competitive semiconductor industry.

The L100 Nanomanipulation System for Life Sciences research and development applications, the latest member of Zyvex's NanoWorks(TM) product line, represents Zyvex's entry into the Life Sciences arena.

Zyvex introduced ten new products in 2003 and expects to release at least twelve new products in 2004.

About the Company
Zyvex Corporation, based in Richardson, Texas, is the first molecular nanotechnology company. Zyvex's vision is to be the leading worldwide supplier of tools, products, and services that enable adaptable, affordable, and molecularly precise manufacturing. Zyvex commercializes nanotechnology to address real-world applications with high-growth potential. Zyvex carries its scientific breakthroughs into key commercial applications in the area of materials, tools, and structures.

Contact Information
Zyvex Corporation is at www.zyvex.com .

For financial information, contact Timothy M. Gilmore, Chief Financial
Officer, at tgilmore@zyvex.com or by phone at 972.235.7881 (ext. 232).

For media inquiries, contact Katharine Green, Director of Corporate
Communications, at kgreen@zyvex.com or by phone at 972.235.7881
(ext. 220).

Source: Zyvex Corporation
Web site: http://www.zyvex.com/